Early indicators of prognosis in fulmitant hepatic failure: an assessment of the King's criteria

doi:10.1016/S0168-8278(97)80010-4

Journal of Hepatology

Volume 26, Issue 1, January 1997, Pages 62-68

https://doi.org/10.1016/S0168-8278(97)80010-4 Get rights and content

Abstract

Background/Aims: An accurate and early assessment of the individual patient is critical in deciding whether liver transplantation is indicated in the treatment of fulmitant hepatic failure. Based on analysis of patients treated between 1973 and 1985, the Liver Unit at King's College Hospital, London, developed a prognostic model to identify patients with a poor prognosis. The present study was done to determine the applicability of this model in fulminant hepatic failure patients seen at our center in the 1990s.

Methods: The records of 145 patients with fulmitant hepatic failure, treated conservatively at Queen Elizabeth Hospital, Birmingham between 1990 and 1994, were analyzed. An additional 81 patients who were transplanted for fulmitant hepatic failure during the same period were excluded from the study.

Results: Application of King's College Hospital criteria at the time of admission to this hospital in the acetaminophen group, had a positive predictive value of 88%, negative predictive value of 65% and predictive accuracy of 71%. The positive predictive value, negative predictive value and predictive accuracy of these criteria for non-acetaminophen-induced fulminant hepatic failure, were 79%, 50% and 68%. Multivariate analysis identified prothrombin time, serum creatinine, white cell count and abnormal potassium levels as independent predictors of mortality in acetaminophen-induced fulmitant hepatic failure; and prothrombin time alone in fulmitant hepatic failure induced by other etiologies.

Conclusions: The King's College Hospital criteria for predicting outcome of fulmitant hepatic failure were found to have a slightly lower predictive accuracy than shown in the original study.

References (27)

C Vickers et al.
Transplantation of the liver in adults and children with fulminant hepatic failure
J Hepatol
(1988)
JG O'Grady et al.
Early indicators of prognosis in fulmitant hepatic failure
Gastroenterology
(1989)
RW Chapman et al.
Liver transplantation for acute hepatic failure?
Lancet
(1990)
DHV van Thiel
When should a decision to proceed with transplantation actually be made in cases of fulminant or sub-fulminant hepatic failure: at admission or when a donor organ is made available?
J Hepatol
(1993)
JH Hoofnagle et al.
Fulminant hepatic failure: summary of a workshop
Hepatology
(1995)
J Rozga et al.
Control of cerebral edema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure
Lancet
(1993)
RT Keays et al.
The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure
J Hepatol
(1993)
PM Harrison et al.
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine
Lancet
(1990)
WM Lee
Medical progress: acute liver failure
N Engl J Med
(1993)
S Iwatsuki et al.
Liver transplantation for fulmitant hepatic failure
Transplant Proc
(1989)

J Bernuau et al.

Multivariate analysis of prognostic factors in fulminant hepatitis B

Hepatology

(1986)

L Pereira et al.

Coagulation factors V and VIII/V ratio as predictors of outcome in paracetamol-induced fulminant hepatic failure: relationship to other prognostic indicators

Gut

(1992)

E Christensen et al.

Prediction of fatality in fulmitant hepatic failure

Scand J Gastroenterol

(1984)

Cited by (194)

The Story of Ammonia in Liver Disease: An Unraveling Continuum
2024, Journal of Clinical and Experimental Hepatology
Hyperammonemia and liver disease are closely linked. Most of the ammonia in our body is produced by transamination and deamination activities involving amino acid, purine, pyrimidines, and biogenic amines, and from the intestine by bacterial splitting of urea. The only way of excretion from the body is by hepatic conversion of ammonia to urea. Hyperammonemia is associated with widespread toxicities such as cerebral edema, hepatic encephalopathy, immune dysfunction, promoting fibrosis, and carcinogenesis. Over the past two decades, it has been increasingly utilized for prognostication of cirrhosis, acute liver failure as well as acute on chronic liver failure. The laboratory assessment of hyperammonemia has certain limitations, despite which its value in the assessment of various forms of liver disease cannot be negated. It may soon become an important tool to make therapeutic decisions about the use of prophylactic and definitive treatment in various forms of liver disease.
An Optimal Prognostic Model Based on Multiparameter Ultrasound for Acute-on-Chronic Liver Failure
2023, Ultrasound in Medicine and Biology
Acute-on-chronic liver failure (ACLF) is associated with a considerably high mortality, and accurate prognosis prediction is critical to navigate intervention decisions and improve clinical outcomes. The objective of this study was to establish a better prognostic model for ACLF based on multiparameter ultrasound in combination with clinical features.
A total of 149 patients with ACLF were prospectively enrolled and underwent conventional ultrasound, 2-D shear wave elastography (SWE), attenuation imaging, color Doppler sonography, superb microvascular imaging and contrast-enhanced ultrasound (CEUS). Univariate and multivariate analyses were performed to identify independent ultrasound signatures for the prognosis of ACLF, which, when integrated with clinical characteristics, were used to establish a prognostic model.
Hepatic perfusion features of CEUS differed significantly between the poor and good prognosis groups, among which the time interval (TI) between peak portal vein (PV) velocity and liver parenchyma (LP) enhancement, TI(PV, LP), was independently associated with the prognosis of ACLF. A prediction model comprising TI(PV, LP) and the international normalized ratio was established, and the area under the curve (AUC) was 0.851, which is greater than those of the Model for End-stage Liver Disease (0.785), fall time of LP model (0.754), 2-D SWE nomogram (0.708) and TI(PV, LP) (0.352). Furthermore, the performance of the model was verified in an independent validation cohort (AUC = 0.920).
The newly developed model performs better than existing tested models; thus, it has potential as a better non-invasive model for predicting the prognosis of patients with ACLF. A future multicenter, large-sample study is required to validate the performance of this model.
Higher circulating natural killer cells and lower lactate levels at admission predict spontaneous survival in non-acetaminophen induced acute liver failure
2021, Clinical Immunology
Massive cellular necrosis in acute liver failure (ALF) is dominantly immune mediated and innate immune cells are major pathophysiological determinants in liver damage.
In fifty ALF and fifteen healthy, immune cells phenotyping by flow-cytometry, DAMPs using ELISA were analysed and correlated with clinical and biochemical parameters.
ALF patients (aged 27 ± 9 yr, 56% males, 78% viral aetiology) showed no difference in neutrophils and classical monocytes, but significantly increased intermediate monocytes (CD14⁺CD16⁺) (p < 0.01), decreased non-classical monocytes (CD14⁻CD16⁺) and CD3^-veCD16⁺CD56⁺ NK cells compared to HC. ALF patients who survived, showed higher NK cells (9.28 vs. 5.1%, p < 0.001) among lymphocytes and lower serum lactate levels (6.1 vs. 28, Odds ratio 2.23, CI 1.27–3.94) than non- survivors had higher. Logistic regression model predicted the combination of lactate levels with NK cell percentage at admission for survival.
In conclusion, Combination of NK cell frequency among lymphocytes and lactate levels at admission can reliably predict survival of ALF patients.
Acute liver failure
2020, Medicine (Spain)
La insuficiencia hepática aguda grave (fallo hepático agudo o fulminante) es una entidad poco frecuente caracterizada por un deterioro de la función hepática en pacientes sin hepatopatía previa conocida, que se manifiesta por la presencia de coagulopatía de origen hepático, ictericia y alteración variable del nivel de consciencia (encefalopatía hepática). La etiología del cuadro es muy variable, desde causas más frecuentes como hepatotoxicidad por diversas sustancias (como paracetamol) o la hepatitis isquémica o vírica, hasta otras mucho menos habituales como la enfermedad de Wilson o el síndrome de Budd-Chiari. En otros casos (hasta el 40%) no se consigue identificar la causa desencadenante. Sin tratamiento, el pronóstico de estos pacientes es pobre, con una mortalidad libre de trasplante incluso superior al 90% en algunos casos, por lo que el reconocimiento a tiempo del cuadro y su manejo de forma precoz resultan fundamentales. Además de medidas generales de soporte, deberá iniciarse el tratamiento específico de la causa (si esta se conoce) siempre que se disponga del mismo. Sin embargo, en muchos casos, ya sea por desconocimiento de la causa desencadenante, ausencia de tratamiento etiológico o de mejoría del paciente a pesar de la instauración del mismo, el trasplante hepático urgente será la única solución posible para estos pacientes.
Severe acute liver failure (acute or fulminant hepatic failure) is a rare disorder characterized by hepatic function deterioration in patients without previous liver disease; it leads to hepatic coagulopathy, jaundice and hepatic encephalopathy (loss of consciousness in variable degree). Etiology varies from hepatoxicity (drug-induced injure, for example paracetamol) the commonest, to ischemic or viral hepatitis; including other causes much less frequent (Wilson's disease and Budd-Chiari syndrome). Triggering cause is not identified in other cases (up to 40%). Without treatment prognosis is poor, and transplant free mortality can exceed 90%; so, on-time diagnosis and early management are mandatory. Together with support measures, cause-specific treatment has to be stablished (if cause is known and treatment is available). However, urgent hepatic transplantation is the only possible treatment for such patients (unknowing triggering cause, etiologic treatment not available or lack of treatment response).
Management of Amanita phalloides poisoning: A literature review and update
2018, Journal of Critical Care
Amanita phalloides poisoning with a high mortality is a serious health problem in the world. The typical clinical manifestations are usually characterized by the absence of any symptoms followed by severe gastrointestinal disorders and acute liver failure. Inhibition of RNA polymeraseII (RNAP II) activity, apoptosis, and oxidative stress are considered as the major mechanism of amatoxins intoxication. The current treatment measures mainly include prevention of amatoxins absorption, elimination of absorbed amatoxins, potential antidotes therapy, and liver transplantation. Nevertheless, there are no widely accepted treatment criteria for Amanita phalloides poisoning. This paper will focus on the treatment measures based on the previous studies and provide the currently available information for clinicians.
Prognostic Models in Acute Liver Failure
2018, Clinics in Liver Disease
Citation Excerpt :
Data on the value of this predictive model have been mixed. In a further attempt to independently recreate and validate this prognostic model, another group of investigators29 applied the aforementioned criteria to a population of 81 patients with ALF and determined that the King’s College Criteria for predicting outcomes of ALF had slightly lower predictive accuracy than that originally suggested in the original O’Grady and colleagues’28 study. The Clichy criterion was developed by Bernuau and colleagues34,35 in 1986 from a multivariate analysis of 115 patients with fulminant hepatitis B infection.

View all citing articles on Scopus

View full text

Early indicators of prognosis in fulmitant hepatic failure: an assessment of the King's criteria

Abstract

J Hepatol

Gastroenterology

Lancet

J Hepatol

Hepatology

Lancet

J Hepatol

Lancet

Medical progress: acute liver failure

N Engl J Med

Liver transplantation for fulmitant hepatic failure

Transplant Proc

Multivariate analysis of prognostic factors in fulminant hepatitis B

Hepatology

Coagulation factors V and VIII/V ratio as predictors of outcome in paracetamol-induced fulminant hepatic failure: relationship to other prognostic indicators

Gut

Prediction of fatality in fulmitant hepatic failure

Scand J Gastroenterol